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Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The NetherlandsSummary IntroductionObjective: Studies on the epidemiology of primary sclerosing
cholangitis (PSC) and primary biliary cirrhosis (PBC) show vari-
able outcome. We aimed at systematically reviewing the inci-
dence and prevalence rates, as well as geographical distribution
and temporal trends of PSC and PBC.
Data sources: A systematic search of literature was performed in
Medline and EMBASE (search last conducted January 10th, 2011).
Study selection: Population-based epidemiological studies
reporting incidence and/or prevalence rates for PSC or PBC in a
deﬁned geographical area of at least 100,000 adult inhabitants
were considered relevant.
Data extraction: Study area, study period, number of patients,
number of inhabitants, incidence per 100,000 inhabitants per
year, prevalence per 100,000 inhabitants, method of case-ﬁnding,
method of case-ascertainment, male/female ratio and in case of
PSC, occurrence of inﬂammatory bowel diseases (IBD) were
extracted from retrieved articles.
Results: The literature search yielded 2286 abstracts of which 31
articles fulﬁlled all inclusion criteria. Studies varied in size from
10 to 770 patients in catchment areas from 100,312 to
19,230,000 inhabitants. The incidence and prevalence rates for
PSC range from 0 to 1.3 per 100,000 inhabitants/year and
0–16.2 per 100,000 inhabitants, respectively. PBC incidence rates
range from 0.33 to 5.8 per 100,000 inhabitants/year and preva-
lence rates range from 1.91 to 40.2 per 100,000 inhabitants; prev-
alence rates are increasing in time.
Conclusions: Incidenceandprevalence ratesofbothPSCandPBCvary
widely and seem to be increasing. True population-based studies are
scarce and therefore large population-based studies combiningmetic-
ulous case-ﬁnding and case-ascertainment strategies are necessary.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Journal of Hepatology 20
Keywords: Primary sclerosing cholangitis; Primary biliary cirrhosis; Epidemiol-
ogy; Incidence; Prevalence.
Received 5 August 2011; received in revised form 29 September 2011; accepted 3
October 2011
⇑ Corresponding author. Address: Dept. of Gastroenterology and Hepatology
Academic Medical Center, Meibergdreef 9, 1100 DD Amsterdam, The Netherlands.
E-mail address: k.boonstra@amc.uva.nl (K. Boonstra).
Abbreviations: PSC, primary sclerosing cholangitis; PBC, primary biliary cirrhosis;
IBD, inﬂammatory bowel disease; UDCA, ursodeoxycolic acid; MOOSE, Meta-
analysisOf Observational Studies in Epidemiology; ICD, International Classiﬁcation
of Diseases; ERCP, endoscopic retrograde cholangiopancreatography; MRCP, mag-
netic resonance cholangiopancreatography; AMA, antimitochondrial antibodies.Primary sclerosing cholangitis (PSC) and primary biliary cirrhosis
(PBC) are enigmatic cholestatic liver diseases ultimately resulting
in cirrhosis and liver failure. Both diseases are considered complex
genetic diseases, but the etiopathogenesis is still unknown [1,2].
PSC is more common in men than in women (2:1) and can occur
at any age with a peak incidence around 40. PSC is strongly associ-
ated with inﬂammatory bowel diseases (IBD), most often ulcera-
tive colitis, and patients have an increased risk for developing
colorectal and hepatobiliary malignancies [3,4]. The course of
PSC is highly variable with reported median survival rates until
liver transplantation or death from 12 to 18 years [5]. PBC on the
other hand predominantly affects middle aged or elderly women
(1:9). Common symptoms associated with PSC and PBC are pruri-
tus, fatigue and upper abdominal discomfort. However, more than
50% of patients are asymptomatic at time of diagnosis [6,7]. Multi-
focal strictures and dilatations of the intra- and/or extra-hepatic
bile ducts seen on cholangiography are hallmarks of PSC, although
these can also be found in secondary sclerosing cholangitis due to
cholelithiasis, biliary surgery, IgG4-associated cholangitis or vari-
ous other causes [8]. Antimitochondrial antibodies directed
against the E2 subunit of the pyruvate dehydrogenase complex
are a sensitive serological hallmark of PBC [9]. Ursodeoxycholic
acid (UDCA) improves serum liver tests, histologic features and
survival of PBCpatients [10–12]. In PSC, the beneﬁcial role of UDCA
in disease progression and survival is still unproven [13,14]. Sev-
eral studies have investigated the epidemiology of both diseases,
using different case-ﬁnding and case-ascertainment strategies.
The reported incidence and prevalence ﬁgures show quite some
variation, dependingon theapplied search strategy, thepopulation
under study, and the scrutiny of case-ﬁnding and ascertainment.
We aimed at systematically reviewing the literature on incidence
and prevalence rates and temporal trends for PSC and PBC.Methods
Literature search
A systematic search of the medical literature was performed using the checklist
proposed by the Meta-analysis Of Observational Studies in Epidemiology
(MOOSE) group with assistance of a clinical librarian, in peer-reviewed medical
databases Medline and EMBASE (search last conducted January 10th, 2011)
[15]. The following strategy was used to search Medline: (((‘‘Cholangitis,
Sclerosing’’[Mesh]) OR (primary sclerosing cholangitis⁄[tiab]) OR (‘‘liver cirrhosis,12 vol. 56 j 1181–1188
after search
n = 2286
Publications selected on 
title and/or abstract
n = 63
Not relevant based on 
title and/or abstract 
n = 2223
Excluded 
n = 32
• No population-based 
epidemiology (n = 15)
• Full-text could not be 
obtained (n = 11)
• Review article (n = 3)
• Duplicate data or 
publication (n = 3)
Publications eligible 
for analysis
n = 31
Publications identified
Fig. 1. Flowchart study selection.
Review
biliary’’[Mesh]) OR (primary biliary cirrhosis⁄[tiab])) AND ((‘‘epidemiology’’[sub-
heading]) OR (epidemiol⁄[tiab]) OR (‘‘Incidence’’[Mesh]) OR (incidenc⁄[tiab]) OR
(prevalen⁄[tiab]) OR (‘‘prevalence’’[Mesh]))).
The following strategy was used to search EMBASE: (((exp primary sclerosing
cholangitis) OR (primary sclerosing cholangitis.ti,ab.) OR (exp primary biliary cir-
rhosis) OR (primary biliary cirrhosis.ti,ab.)) AND ((exp EPIDEMIOLOGY/) OR (epi-
demiol⁄.ti,ab.) OR (exp INCIDENCE/) OR (incidenc⁄.ti,ab.) OR (prevalen⁄ti,ab.) OR
(exp PREVALENCE/))).
Selection criteria
Two authors (KB and CYP) independently screened title and abstract of identiﬁed
articles. Population-based epidemiological studies depicting incidence and/or
prevalence rates for PSC or PBC in a deﬁned geographical area of at least
100,000 adult inhabitants were considered relevant. Full articles of potentially
relevant studies were retrieved for further analysis. Disagreement was resolved
by discussion. Review articles were excluded from both search strategies. There
were no language restrictions.
Data extraction
The following data were extracted and analyzed per study: study area, study per-
iod, number of patients, number of inhabitants, incidence per 100,000 inhabitants
per year, prevalence per 100,000 inhabitants, method of case-ﬁnding, method of
case-ascertainment, male/female ratio and in case of PSC, occurrence of inﬂam-
matory bowel diseases. When the full text of an article was missing, the corre-
sponding author was asked to provide complementary data.
Quality assessment
Appraisal of study quality was based on (1) deﬁnition of studied population, (2)
case-ﬁnding method and (3) case-ascertainment criteria. The study quality was
considered ‘good’ when a case-ﬁnding method combined several hospital dat-
abases in a deﬁned catchment area and when a well-directed case-ascertainment
was performed using established diagnostic criteria. Quality was considered
‘moderate’ when the case-ﬁnding strategy was insufﬁcient with a reasonable
chance to miss cases or case-ascertainment was not performed by an expert panel
using established diagnostic criteria. The quality of a study was considered ‘poor’
when case-ﬁnding or case-ascertainment had not been performed.Results
The search yielded 2286 abstracts of which 30 articles in English
and one in Norwegian were eligible for inclusion. Two thousand
two hundred and twenty three articles were excluded based on
title and abstract. For the remaining 63 articles, reasons for exclu-
sion are depicted in Fig. 1.Study characteristics
Of included articles, 19 reported incidence or prevalence rates in
Europe [16–34], seven in North-America [35–41], three in Asia
[42–44], and two in Australia [45,46]. Studies varied in size from
10 to 770 patients in catchment areas from 100,312 to 19,230,000
inhabitants.
Various sources had been used for case-ﬁnding purposes. In
17 studies, a search was performed in a medical record database
using the International Classiﬁcation of Diseases (ICD) or a simi-
lar diagnosis coding system. Other sources were laboratory dat-
abases, pathology databases, personal registry of physicians,
radiological databases, hospital billing system and death certiﬁ-
cates. Of the 31 included studies, 13 (41.9%) used one source
for case-ﬁnding, three studies (9.7%) used two sources, seven
studies (22.6%) used three sources, ﬁve studies (16.1%) used four
sources, two studies (6.5%) used ﬁve sources and one study (3.2%)1182 Journal of Hepatology 2012combined six sources for case-ﬁnding. An overview is given in
Tables 1 and 2. A quality assessment of case-ﬁnding and case-
ascertainment methods is presented in Table 3. Studies of good
quality are highlighted in Tables 1 and 2 and incidence and prev-
alence rates are shown in Figs. 2 and 3.
PSC
Eleven studies on the epidemiology of PSC from 1984 till 2005
were identiﬁed of which four fulﬁlled quality criteria for both
case-ascertainment and case-ﬁnding. Three were performed in
North America between 1976 and 2005, reporting incidence rates
ranging from0 to 0.92 per 100,000 inhabitants per year [37,39,40].
In Alaska, no PSC patients were identiﬁed between 1984 and 2000
[37]. In Canada, 49 PSC patients were diagnosed in a 5-year period
in a population of 1,112,521 corresponding to an incidence rate of
0.92 per 100,000 inhabitants per year [40]. One prospective popu-
lation-based study fromNorway included 17 newly diagnosed PSC
patients in a 10-year period, between 1986 and 1995, resulting in
an incidence rate of 1.31 per 100,000, still the highest incidence
rate for PSC found worldwide [27].
Eight studies reported the proportion of concomitant IBD in
PSC patients ranging from 20% in Singapore up to 76% in Sweden
[27,31–34,39,40,44]. When combining studies that met all qual-
ity criteria, the average proportion of IBD in PSC patients was
70% (67–73%) [27,39,40]. Temporal trends in PSC incidence were
reported in four studies, all of which demonstrated increasing
incidence rates in time [31,34,40,32].
PBC
Twenty-four studies describing incidence and/or prevalence rates
between 1972 and 2007 for PBC were identiﬁed. When consider-
ing studies of good quality only, the lowest and highest incidence
rates for PBC were both found in Newcastle Upon Tyne, Unitedvol. 56 j 1181–1188
Table 1. Incidence and prevalence of primary sclerosing cholangitis.
Study, [Ref.]
Country
Period No. of 
patients
Population Case-
ascertainmenta
Incidence§ 
(95% CI)
Prevalence§ 
(95% CI)
IBD
(%)
Male
(%)
Escorsell et al., [31] 
Spain
1984-1988 43 19,230,000 Personal registry gastroenterologists 
and hepatologists
I + II + III + IV 0.07 0.22 47 60
Berdal et al., [24] 
Akershus, Norway
1985-1994 12 180,000 ICD-9 III 0.7 5.6 n.a. 58
Byron et al., [35] 
Winnipeg, Canada
1987-1994 39 650,000 All clinical records referral center II + III + VI or 
II + IV + VI
n.a. 6.5 n.a. n.a.
Boberg et al., [27] 
Oslo, Norway
1986-1995 17 130,000 Prospective registration II + III + IV 1.3 
(0.8-2.1)
8.5 
(2.8-14.2)
71 71
Ang et al., [44] 
Changi, Singapore
1989-1998 10 750,000 10 consecutive patients III + IV n.a. 1.3 20 90
Bambha et al., [39] 
Olmsted County, US
1976-2000 22 ? Medical records linkage system, 
pathology reports, laboratory 
reports, IBD research records
I + II + III + V or 
I + II + IV + V
0.9 13.6 73 68
Hurlburt et al., [37] 
Alaska, US
1984-2000 0 100,312 All clinical records, ICD-9 III 0 0 n.a. n.a.
Card et al., [32] 
UK
1987-2002 223 2,027,909 General Practice Research 
Database
n.a. 0.41 
(0.34-
0.48)
3.85 
(3.04-4.80)
48 63.5
Kingham et al., [33] 
Swansea, UK
1984-2003 46 251,000 Prospective registration I + II + III + IV 0.91 12.7 62 62
Lindkvist et al., [34] 
Västra Götaland, 
Sweden
1992-2005 199 1,492,000 ICD-9 and ICD-10 II + III + V 1.22 16.2 76 71
Kaplan et al., [40] 
Alberta, Canada
2000-2005 49 1,112,521 ERCP database, review of MRCPs, 
pathology database, ICD-9, ICD-10
II + III + V or 
II + IV + V
0.92 n.a. 67 55
Case-finding
Studies fulﬁlling all quality criteria regarding (1) deﬁnition of studied population, (2) case-ﬁnding method, and (3) case-ascertainment criteria are highlighted in blue.
aCase-ascertainment criteria: I, clinical features; II, serum AP" P6 months; III, ERCP
inﬂammatory bowel disease.
§Per 100,000 inhabitants.
ICD, International Classiﬁcation of Diseases; IBD, inﬂammatory bowel disease; ERCP, endoscopic retrograde cholangiopancreatography; MRCP, magnetic resonance chol-
angiopancreatography; n.a., not available; ?, unknown.
JOURNAL OF HEPATOLOGYKingdom, 0.9 per 100,000 inhabitants per year in 1977 and 5.8 per
100,000 inhabitants per year in 1994, respectively [16,26]. The
highest prevalence rate for PBC of 40.2 per 100,000 age- and sex-
matched inhabitants was found in 1995 in Olmsted County, Min-
nesota, USA [36]. When combining studies, the mean proportion
of female patients was 92% (76–100%). All eight studies depicting
yearly prevalence rates for several consecutive years reported
increased prevalence rates in time (Fig. 4) [19,22,23,25–27,30,38].
Key Points
• Incidence and prevalence rates for both PSC and PBC 
vary widely and seem to be increasing in time
• The incidence and prevalence rates for PSC range 
from 0-1.3 per 100,000 inhabitants/year and 0-16.2 per 
100,000 inhabitants, respectively
• For PBC, the incidence and prevalence rates range from 
0.33-5.8 per 100,000 inhabitants/year and 1.91-40.2 per 
100,000 inhabitants, respectively
• Most epidemiological studies are performed in the 
Western world and true population-based studies are 
scarce. Proper epidemiological data may help to identify 
etiologic factors for these complex diseases. Hence, 
large population-based studies are warrantedJournal of Hepatology 2012Discussionor MRCP; IV, liver biopsy; V, no signs of secondary sclerosing cholangitis; VI,This systematic review yielded a wide range in incidence and
prevalence rates as well as study quality for PSC and PBC in Eur-
ope, North America, Asia and Australia. The incidence and preva-
lence rates for PSC range from 0 to 1.3 per 100,000 inhabitants/
year and 0–16.2 per 100,000 inhabitants, respectively. In case
of PBC, incidence rates range from 0.33 to 5.8 per 100,000 inhab-
itants/year and prevalence rates range from 1.91 to 40.2 per
100,000 inhabitants. Several causes may underlie the differences
found. Improvement of diagnostic tools, increasing disease
awareness, and digitalized patient registration likely contributed
to the rising incidence and prevalence rates. In 1970, gastroente-
rologists were able for the ﬁrst time to successfully cannulate the
papilla of Vater and selectively intubate the ducts using a duode-
noscope with omnidirectional angulation, the ﬁrst ERCP [47]. A
disadvantage of ERCP is the risk of pancreatitis, bleeding or per-
foration. More than 20 years after the introduction of ERCP, MRCP
was introduced making it possible to visualize the intra- and
extra-hepatic ducts without the risks associated with ERCP [48].
The introduction of MRCP lowered the threshold for diagnostic
imaging and may have resulted in a higher frequency of cholan-
giographies diagnosing PSC. In 1965, antimitochondrial antibod-
ies were identiﬁed as the most important serological marker for
PBC [49]. At that time there was no effective treatment available,
but that changed in 1982 when the ﬁrst trials were initiated
administering UDCA at a dose of 13–15 mg/kg daily, with goodvol. 56 j 1181–1188 1183
Table 2. Incidence and prevalence of primary biliary cirrhosis.
Study, [Ref.]
country
Period No. of 
patients
Population Case-
ascertainmentb
Incidence§
(95% CI)
Prevalence§
(95% CI)
Male
(%)
Hamlyn et al., [16] 
Newcastle upon 
Tyne, UK
1972-1977 117 2,080,000 Personal registry physicians, positive AMA I + IIb + III 0.9 n.a. 7
Triger et al., [17] 1977-1979 34 520,000 Personal registry physicians, positive AMA 
results
I + IIb + III 0.58 5.4 6
Danielsson et al., [18] 
Northern Sweden
1973-1982 111 570,000 Personal registry physicians, hospital patient 
registry, positive AMA results
I + IIb or I + IIb 
+ III
1.3 15.1 14
Eriksson et al., [19] 
Malmö, Sweden
1973-1982 33 240,000 Autopsy reports I + IIb + III 2.4 9.6 24
Löfgren et al., [20] 
Örebro, Sweden
1976-1983 18 164,063 Positive AMA results I + IIb + III 1.4 12.8 22
Almdal et al., [21] 
Denmark
1981-1985 233 5,100,000 Hospital admission registry - 0.9 n.a. 24
Myszor et al., [22] 
Newcastle, UK
1965-1987 411 1,920,000 Hospital admission registry, positive AMA 
results, personal registry physicians
I + IIb + III or 
I + IIb
1.98 15.35 10
Witt-Sullivan et al., 
[41] Ontario, Canada
1986-1988 225 ? Personal registry physicians I + III 0.33 2.24 n.a.
Watson et al., [45] 
Victoria, Australia
1990-1991 84 4,390,000 Personal registry physicians, hospital 
discharge registry, positive AMA results
I + IIb + III or 
I + IIb
n.a. 1.91 8
Remmel et al., [23] 
Estonia
1973-1992 69 1,526,177 Personal registry physicians, positive AMA 
results
I + IIb + III 0.39 2.69 5
Berdal et al., [24] 
Akershus, Norway
1985-1994 21 180,000 ICD-9  I + IIb + III 1.2 12 0
James et al., [25] 
North-East England, 
UK
1987-1994 770 2,052,668 Personal registry physicians, ICD-9, ICD-10, I + IIb + III or 
I + IIb
3.22 33.46 8
Metcalf et al., [26] 
Newcastle upon 
Tyne, UK
1987-1994 160 285,310 Personal registry physicians, ICD-9, positive 
pathology reports
I + IIb + III or 
I + IIb
5.8 39.2 10
Byron et al., [35] 
Winnipeg, Manitoba, 
Canada
1987-1994 52 650,000 All clinical records referral center I + IIb + IV n.a. 8 n.a.
Kim et al., [36] 
Olmsted County, US
1975-1995 46 ? Medical record database, pathology 
database, positive AMA results
I + II or I + III 2.7 40.2 11
Boberg et al., [27] 
Oslo, Norway
1986-1995 21 130,000 Prospective registration I + II + III or 
I + II + IV
1.6
(1.0-2.5)
14.6 
(7.1-11.1)
24
Rautiainen et al., [28] 
Finland
1988-1999 545 2,972,189 ICD-9, ICD-10, pathology registry, personal 
registry physicians, discharge database 
transplantation unit
I + IIb + III 1.7
(1.5-2.0)
18.0 
(17.2-18.9)
13
Hurlburt et al., [37] 
Alaska, US
1984-2000 18 100,312 All clinical records, ICD-9 I + IIb + III n.a. 16 0
Eaton et al., [29] 
Denmark
1977-2001 666 5,472,032 ICD-8, ICD-10 - n.a. 12 n.a.
Pla et al., [30] 
Sabadell, Spain
1990-2002 87 389,758 Prospective registration, personal registry 
physicians, pathology registry, positive AMA 
results, hospital medical record system
I + II + III 1.72 19.5 3
Sood et al., [46] 
Victoria, Australia
1990-2002 249 4,880,000 Personal registry physicians, database liver 
transplantation unit, medical record search, 
positive AMA results
I + IIb + III n.a. 5.1 11
Myers et al., [38] 
Alberta, Canada
1996-2002 137 1,100,000 Physician claims database, inpatient 
discharge abstract database, ambulatory 
I + IIb + III 3.03 22.7 17
Delgado et al., [42] 
Southern, Israel
1993-2004 47 826,000 Personal registry physicians, liver 
transplantation registry, ICD-9, positive 
AMA results, pathology registry, autopsy 
I + II + III n.a. 5.5 0
Chong et al., [43] 
Brunei Darussalam
2007 10 390,000 Hepatology clinics register, pathology 
register, pharmacy database
I + IIb + III 1.0 2.6 0
Case-finding
results, death certificates
Sheffield, UK
positive AMA results, death certificates
AMA results, death certificates, liver
care classification system detabase
certificates
Studies fulﬁlling all quality criteria regarding (1) deﬁnition of studied population, (2) case-ﬁnding method, and (3) case-ascertainment criteria are highlighted in blue.
bCase-ascertainment criteria: I, AMA; IIa, serum AP" P6 months; IIb, cholestatic liver parameters; III, liver biopsy; IV, IgM".
§Per 100,000 inhabitants.
AMA, antimitochondrial antibodies; ICD, International Classiﬁcation of Diseases; n.a., not available; ?, unknown.
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Fig. 2. Incidence of primary sclerosing cholangitis and primary biliary
cirrhosis (considering high quality studies only).
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Table 3. Quality assessment of all included studies.
Study, yr [Ref.]
of study 
population
Case- Case-
ascertainment
Chong et al., 2010 [43] + + +
Myers et al., 2009 [38] + + +
Kaplan et al., 2007 [40] + + +
Pla et al., 2007 [30] + + +
Rautiainen et al., 2007 [28] + + +
Delgado et al., 2005 [42] + + +
Bambha et al., 2003 [39] + + +
Hurlburt et al., 2002 [37] + + +
Kim et al., 2000 [36] + + +
James et al., 1999 [25] + + +
Boberg et al., 1998 [27] + + +
Metcalf et al., 1997 [26] + + +
Danielsson et al., 1990 [18] + + +
Myszor et al., 1990 [22] + + +
Hamlyn et al., 1983 [16] + + +
Lindkvist et al., 2010 [34] + ± +
Sood et al., 2004 [46] + ± +
Berdal et al., 1998 [24] + ± +
Remmel et al., 1995 [23] + ± +
Watson et al., 1995 [45] + ± +
Löfgren et al., 1985 [20] + ± +
Triger et al., 1980 [17] + ± +
Kingham et al., 2004 [33] + ? +
Byron et al., 1996 [35] + - +
Eriksson et al., 1984 [19] + ? +
Card et al., 2008 [32] + ± -
Eaton et al., 2007 [29] + ± -
Ang et al., 2002 [44] + ? ±
Almdal et al., 1991 [21] + - -
Witt-Sullivan et al.,1990 [41] - - ±
Escorsell et al.,1994 [31] - - ±
Definition
finding
+, good; ±, moderate; -, absent or poor; ?, unknown.
Studies are ranged according to quality assessment score and year of publication
with last published highest.
Scoring studies on top.
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Fig. 3. Prevalence of primary sclerosing cholangitis and primary biliary
cirrhosis (considering high quality studies only). ⁄No PSC patients during a
17-year study period.
JOURNAL OF HEPATOLOGYresults [50]. Improvement of diagnostic tools and disposition of
therapeutic modalities likely play a role in increasing prevalence
over time, but may also contribute to global differences since
these tools and therapies are not equally distributed around the
world.
The introduction of computers in healthcare has been a big
leap forward in clinical epidemiological research. Case-ﬁnding
became easier and more accurate after the introduction of digital-
ized laboratory and pathology databases. Although some studies
in the seventies and eighties seemed well performed, the increase
in incidence and prevalence rates, especially for PBC, is in all
probability partly attributable to a more exhaustive case-ﬁnding
strategy using computer databases. The method stated by MetcalfJournal of Hepatology 2012 vol. 56 j 1181–1188 1185
Review
and James already published in 1997 is an excellent example of a
meticulous case-ﬁnding strategy and has set a standard for sub-
sequent studies [51]. These guidelines include: stringent case
inclusion criteria; deﬁnition of date of disease onset; well-
deﬁned study period, area and population; multiple case ﬁnding
methods and rigorous tracing of all possible cases [51]. Temporal
trends may partly be explained by these technological develop-
ments and case-ﬁnding strategies, yet increasing incidence and
prevalence rates in time are even observed within studies. Other
factors like the ones discussed below, may play a role in increas-
ing incidence and prevalence rates and geographical differences.
PSC
Although true population-based studies are lacking for PSC, two
factors seem to play a signiﬁcant role in the global distribution
of the disease: a variable frequency of IBD around the world
and differences in HLA-susceptibility among ethnic groups caus-
ing population differences. A recent review combining 47 studies
concerning the epidemiology of Crohn’s disease showed a wide
variety in incidence and prevalence rates with the highest num-
bers found in Northern Europe, New Zealand and North America,
and lowest numbers in South America, Africa and Asia [52].
Recently, a large PSC cohort listed for liver transplantation in
the United States was clinically and genetically investigated.
The authors were able to demonstrate that the risk of being listed
for liver transplantation is signiﬁcantly associated with ancestral
origin and that phenotype differences in PSC exist across ethnic-
ities [53].
Based on these reports, the genetic background seems to play
a signiﬁcant role in the etiology and global distribution of the dis-
ease. Unfortunately, no population-based epidemiological studies
were performed in Africa or Asia. One study from Singapore falls
short in proper case-ﬁnding method, hence it is difﬁcult to draw
conclusions [44]. Three out of four of the highest scoring studies
were performed in North America. An outlier among these well-
conducted studies in North America is a study published in 2002
[37]. Clinical records of all cases of autoimmune liver disease at
the Alaska Native Medical Center from 1983 till June 2000 were
reviewed. Only one referral center in a population of 100,312 pro-
vides a solid foundation for an epidemiological study, even
though the authors estimate that 10–20% of Alaska natives seek
medical care outside the health care delivery system. Strikingly,
no PSC patients were found in a 17-year period. A possible expla-
nation may be the low incidence of inﬂammatory bowel disease
in this population consisting of Eskimo’s, Aleuts and Indians.
With a catchment area of 19,230,000 inhabitants, the study of
Escorsell et al. in Spain between 1984 and 1988 is the largest ever
conducted [31]. Unfortunately, the case-ﬁnding and case-ascer-
tainment method based on a questionnaire sent to gastroenterol-
ogists and hepatologists is insufﬁcient for population-based
epidemiology.
Recently, a systematic review and meta-analysis of the inci-
dence of PSC has been published. Six population-based studies
form North America and Europe resulted in a combined incidence
rate of 1.0 (0.82–1.17) per 100,000 inhabitants [54]. Incidence
rates did not differ when stratiﬁed for continent. However, the
study from the Alaska Native Medical Center was not included
in this analysis.1186 Journal of Hepatology 2012PBC
Between 1972 and 2007, 23 articles have been published describ-
ing incidence and prevalence of PBC. Since the introduction of the
guidelines for proper epidemiological studiesbyMetcalf and James
in1997, thequality of studies improved [51]. Thehighest incidence
and prevalence rates to date have been found in Olmsted County,
USA, andNewcastle upon Tyne, UK, pointing towards possible geo-
graphic or genetic risk factors.However, until 2005no studieswere
performed outside theWesternworld. In 2005, the ﬁrst study from
the Middle East was published, identifying 47 women in Southern
Israel resulting in an overall prevalence rate of 5.5 per 100,000
inhabitants, a 7-fold lower prevalence rate compared to the UK
and USA [42]. Five years later, an even lower prevalence rate was
found inBruneiDarussalam, SoutheastAsia [43]. Tenpatientswere
identiﬁed in a catchment area of 390,000 inhabitants. Strikingly,
the prevalence rate in the Chinese population was almost twice
as high as in the Malay population (4.1 per 100,000 and 2.3 per
100,000, respectively), though the small number of patients is a
limitation of the study. Notable differences in sex ratiowere found.
At present, it remains unclear whether there is a true variation in
sex ratio among populations of different geographical areas with
different ethnic backgrounds or if this is a consequence of varying
studyquality.The current hypothesis regarding etiology is that PBC
is a complex genetic autoimmune disease, meaning that a combi-
nation of genetic susceptibility and environmental factors triggers
disease. Besides infectious and life-style factors, several environ-
mental triggers for PBC have been suggested in the last thirty years
and thesemaypartly account for differences in geographical distri-
bution. Triger published a study in 1980 revealing a cluster of PBC
patients in Shefﬁeld, UK [17]. Almost all patients in this cluster
received water from a single water source. However, chemical
analysis of the water did not unravel a potential trigger. Twenty
years later, another study from the UK showed strong variations
in geographical distribution of patients in Northeast England, but
this distribution could not be explained by geographical or demo-
graphic features [55]. In New York, a signiﬁcant association
between a cluster of PBC patients and superfund toxic waste sites
contaminated with volatile aromatic hydrocarbons and trichloro-
ethylene was identiﬁed, supporting the hypothesis that environ-
mental toxins play a role in development of PBC [56]. In
conclusion, incidence and prevalence rates of both PSC and PBC
varywidely and seem to be increasing. True population-based epi-
demiological studies are scarce, especially in PSC, so it is unclear
whether these are true variations or due to methodological differ-
ences. Proper worldwide epidemiological data may help identify-
ing etiologic factors for these complex diseases. Hence, large
population-based studies combining meticulous case-ﬁnding and
case-ascertainment strategies as stated by Metcalf and James are
necessary andmayprovide clues as to possible genetic background
and environmental risk factors for these chronic cholestatic
diseases.Conﬂict of interest
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